3 Asian Stocks Estimated To Be Undervalued By Up To 44.1%

As global markets experience a surge, with the U.S. indices hitting record highs and Asian markets like Japan and China showing strong gains, investor interest in undervalued stocks is growing. In such an environment, identifying stocks that are potentially undervalued can offer opportunities for investors looking to capitalize on market movements while considering factors like trade agreements and economic policies that influence stock valuations.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name Current Price Fair Value (Est) Discount (Est) Strike CompanyLimited (TSE:6196) ¥3705.00 ¥7290.78 49.2% Polaris Holdings (TSE:3010) ¥211.00 ¥416.25 49.3% MicroPort CardioFlow Medtech (SEHK:2160) HK$0.89 HK$1.76 49.6% Medley (TSE:4480) ¥3180.00 ¥6250.17 49.1% Livero (TSE:9245) ¥1717.00 ¥3380.20 49.2% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1679.50 49.9% GCH Technology (SHSE:688625) CN¥30.58 CN¥60.27 49.3% cottaLTD (TSE:3359) ¥439.00 ¥860.97 49% China Kings Resources GroupLtd (SHSE:603505) CN¥21.72 CN¥42.59 49% Bloks Group (SEHK:325) HK$141.20 HK$279.47 49.5%

Click here to see the full list of 286 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Shanghai Conant Optical

Overview: Shanghai Conant Optical Co., Ltd. is a company that manufactures and sells resin spectacle lenses across Mainland China, the Americas, Asia, Europe, Oceania, and Africa with a market cap of HK$17.95 billion.

Operations: The company generates CN¥2.06 billion in revenue from its manufacturing and sales of resin spectacle lenses across various global markets.

Estimated Discount To Fair Value: 44.1%

Shanghai Conant Optical appears undervalued based on cash flow analysis, trading at HK$37.4, significantly below its estimated fair value of HK$66.85. The company reported robust financial performance with net income rising to CNY 428.28 million for 2024 and earnings per share increasing to CNY 1.03 from the previous year. Future earnings are forecasted to grow annually by 18%, outpacing the Hong Kong market's expected growth rate of 10.4%.

In light of our recent growth report, it seems possible that Shanghai Conant Optical's financial performance will exceed current levels. Click here to discover the nuances of Shanghai Conant Optical with our detailed financial health report.SEHK:2276 Discounted Cash Flow as at Jun 2025

True Corporation

Overview: True Corporation Public Company Limited, along with its subsidiaries, offers telecommunications and value-added services in Thailand with a market capitalization of approximately THB383.53 billion.

Operations: The company's revenue segments consist of Mobile services generating THB171.52 billion, Pay TV contributing THB6.79 billion, and Broadband Internet and Others bringing in THB27.79 billion.

Story Continues

Estimated Discount To Fair Value: 29.8%

True Corporation is trading at THB 11.1, significantly below its estimated fair value of THB 15.82, indicating it may be undervalued based on cash flows. Despite a forecasted revenue decline of 0.5% annually over three years, earnings are expected to grow by over 71% per year as the company becomes profitable, which surpasses market averages. Recent leadership changes and improved Q1 results—with net income reaching THB 1.63 billion—underscore potential for performance enhancement amidst strategic shifts.

The analysis detailed in our True Corporation growth report hints at robust future financial performance. Dive into the specifics of True Corporation here with our thorough financial health report.SET:TRUE Discounted Cash Flow as at Jun 2025

Xiangyu MedicalLtd

Overview: Xiangyu Medical Co., Ltd is involved in the research, development, manufacturing, and marketing of rehabilitation and physiotherapy equipment with a market cap of CN¥6.79 billion.

Operations: The company generates revenue primarily from its Medical Devices segment, which amounts to CN¥760.48 million.

Estimated Discount To Fair Value: 14.1%

Xiangyu Medical Ltd, trading at CNY 44.02, is valued below its estimated fair value of CNY 51.22, suggesting potential undervaluation based on cash flows. Despite a decline in net profit margins from the previous year and a volatile share price recently, earnings are expected to grow significantly at 32.39% annually over the next three years—outpacing market averages—while revenue growth is forecasted at 17.5% per year. However, dividend coverage remains weak against free cash flows.

Our comprehensive growth report raises the possibility that Xiangyu MedicalLtd is poised for substantial financial growth. Unlock comprehensive insights into our analysis of Xiangyu MedicalLtd stock in this financial health report.SHSE:688626 Discounted Cash Flow as at Jun 2025

Summing It All Up

Click this link to deep-dive into the 286 companies within our Undervalued Asian Stocks Based On Cash Flows screener. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready To Venture Into Other Investment Styles?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:2276 SET:TRUE and SHSE:688626.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments